Myriad Genetics (NASDAQ:MYGN – Get Free Report) updated its fourth quarter 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.030-0.040 for the period, compared to the consensus estimate of 0.030. The company issued revenue guidance of $209.0 million-$211.0 million, compared to the consensus revenue estimate of $212.8 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.
Myriad Genetics Trading Down 4.2 %
NASDAQ:MYGN opened at $13.68 on Wednesday. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -10.52 and a beta of 1.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics has a 1 year low of $12.87 and a 1 year high of $29.30. The business has a fifty day moving average of $15.05 and a 200-day moving average of $22.17.
Wall Street Analyst Weigh In
MYGN has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. StockNews.com upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Piper Sandler cut their price objective on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th. Finally, UBS Group assumed coverage on Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 target price on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $24.27.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Further Reading
- Five stocks we like better than Myriad Genetics
- Consumer Discretionary Stocks Explained
- 3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 REITs With Big Dividend Growth and Sustainable Payouts
- 3 Monster Growth Stocks to Buy Now
- Can Integrated Healthcare Stocks Succeed in Public Markets?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.